A commonly used vaccine has received FDA approval for a Phase II clinical trial to test its ability to reverse long-standing type 1 diabetes. The announcement was made at the 75th Scientific Sessions of the American Diabetes Association (ADA) by Associate Professor Denise Faustman from Massachusetts General Hospital.
The vaccine is known as bacillus Calmette-Guérin (BCG), and has been used for over 90 years as a vaccine for tuberculosis, and more recently as a treatment for bladder cancer. A 2012 pilot study in adults with long standing type 1 diabetes showed that two injections of BCG spaced 4 weeks apart temporarily reduced the number of auto-reactive killer T cells and increased the number of beneficial regulatory T cells. The vaccine was able to transiently increase the amount of c-peptide in the blood, indicating some restoration of islet function and insulin secretion. Read More
T1DCRN researcher Professor Thomas Kay from St Vincent’s Institute in Melbourne and an international team of specialists have developed a new four-stage treatment plan to tackle problematic hypoglycaemia.
Severe hypoglycaemia is experienced by a third of people with type 1 diabetes at least once per year, when they will require another person to assist them in recovery. Severe hypoglycaemia can usually be explained by exercise, alcohol or errors in insulin dose, but in some people it is unpredictable and can occur seemingly without explanation. This problematic hypoglycaemia has significant impacts on health and quality of life, but can be difficult to treat. Read More
Incorporating data collected in interviews with leading Australian clinical researchers, the Resource Map has identified five key areas in the research development pipeline that could accelerate, expand, and increase the impact of Australian type 1 diabetes clinical research. Read More